GIST with a twist--upregulation of PDGF-B resulting in metachronous gastrointestinal stromal tumor and dermatofibrosarcoma protuberans.
AffiliationDepartment of Surgery, The Royal College of Surgeons in Ireland, Beaumont Hospital, Dublin 9, Ireland. firstname.lastname@example.org
Gastrointestinal Stromal Tumors
Neoplasms, Second Primary
Proto-Oncogene Proteins c-sis
Receptor, Platelet-Derived Growth Factor alpha
MetadataShow full item record
CitationGIST with a twist--upregulation of PDGF-B resulting in metachronous gastrointestinal stromal tumor and dermatofibrosarcoma protuberans. 2010, 14 (2):398-403 J. Gastrointest. Surg.
JournalJournal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
AbstractA 61-year-old male was referred following an incidental radiological discovery of an intra-abdominal mass. His medical history included excision of a lumbar dermatofibrosarcoma protuberans (DFSP) 5 years previously. A CT scan of the abdomen revealed a mass arising from the greater curvature of the stomach. Upper GI endoscopy was normal. He underwent successful laparoscopic resection of this mass.
The histology of the abdominal mass revealed a gastrointestinal stromal tumor (GIST) with poor prognostic indicators. Immunohistochemical analysis of the GIST and his previous DFSP was performed.
Immunohistochemistry suggested a link between the GIST and his previous DFSP involving the PDGF signalling system.
Both GIST and DFSP are extremely rare tumors. A mutation in the platelet-derived growth factor receptor alpha (PDGFR-alpha) has been described in 5-15% of GISTs. It has been shown that DFSP is frequently associated with a translocation between PDGF-B (Chr 22) and COL1A1 (Chr 17), causing continuous activation of PDGFR-beta. Literature review confirms that there are no previously reported cases of both of these tumors occurring in the same patient.
We hypothesize that this patient may have a previously undescribed genetic mutation involving the PDGF signalling system, resulting in these two very rare malignancies. Immunohistochemistry studies confirmed the link on this occasion. Improvements in our understanding of the molecular biology of the PDGF system may novel therapeutic targets in the future.
- Dermatofibrosarcoma protuberans and gastrointestinal stromal tumor as models for targeted therapy in soft tissue sarcomas.
- Authors: Koseła-Paterczyk H, Rutkowski P
- Issue date: 2017 Dec
- Myxoid dermatofibrosarcoma protuberans: clinicopathologic, immunohistochemical, and molecular analysis of eight cases.
- Authors: Mentzel T, Schärer L, Kazakov DV, Michal M
- Issue date: 2007 Oct
- Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis.
- Authors: Sjöblom T, Shimizu A, O'Brien KP, Pietras K, Dal Cin P, Buchdunger E, Dumanski JP, Ostman A, Heldin CH
- Issue date: 2001 Aug 1
- PDGFB rearrangement in dermatofibrosarcoma protuberans: correlation with clinicopathologic characteristics and clinical implications.
- Authors: Ha SY, Lee SE, Kwon MJ, Kim YJ, Lee EH, Seo J, Jang KT, Lee J, Choi YL
- Issue date: 2013 Jul
- Analysis of mutation and expression of c-kit and PDGFR-alpha gene in gastrointestinal stromal tumor.
- Authors: Zheng S, Chen LR, Wang HJ, Chen SZ
- Issue date: 2007 Dec